India-EU trade pact strengthens pharma sector, elevates global healthcare role
The India-European Union (EU) Free Trade Agreement (FTA) represents a significant opportunity for India's pharmaceutical sector, opening doors to a $572.3 billion market while reinforcing India's global healthcare leadership, reports The Pharma Letter’s India correspondent.
In an era of 'China Plus One' strategies, the FTA codifies India’s role as a reliable, rules-based partner in the global life sciences value chain, moving beyond generic volume to high-value clinical and surgical innovation.
While the FTA dramatically reshapes pharmaceutical trade by slashing tariffs from 11% to near-zero for Indian pharma exports to the EU and reducing duties on EU medical devices, the deal also places a clear spotlight on quality, compliance and long-term capability building.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze